Intra-arterial injection of zolpidem and substance misusers
Dear Editors -Hypnotics have long been drugs of abuse by both substance misusers and patients attending adult psychiatric and general practitioner clinics. Zolpidem is licensed for the short term treatment of insomnia. However, we are seeing an increasing amount of abuse of zolpidem particularly among intravenous drug users (IDU).
Zolpidem abusers can take the drug orally, intravenously or by crushing or snorting it. Zolpidem abuse can occur in those who use or are prescribed it for longer than is recommended (four to six weeks) and at doses higher than 10mg-20mg. Its affects are also enhanced when used with other substances such as alcohol. Dependence and withdrawal is commonly seen in chronic users of the drug. 3 A case report detailed the history of a lady who experienced epileptic seizures following abrupt withdrawal of zolpidem following a history of chronic use at high doses. 1 Other reported side effects include hallucinations, delusions, ataxia, euphoria, impulsivity and amnesia. Intravenous abuse is particularly hazardous as doses as small as 5mg can produce serious effects.
In the Drug Treatment Centre and Advisory Board we have more recently seen one serious consequence associated with injection of zolpidem by intravenous drug users (IDU). Two patients who regularly injected zolpidem developed 'arterial microspasm' and this resulted in 'tissue necrosis and the possibility of loss of large areas of skin and digits' according to their consultant vascular surgeon.
Both patients had a history of intravenous drug use and had injected zolpidem a number of times previously. On one occasion within hours of injecting both patients complained of severe pain, difficulty weight bearing and a noticeable change in colour in the skin in one of their feet. One patient reported that they boiled two tablets of zolpidem and injected it into their foot, while the other patient reported crushing two tablets and injecting into their groin. They denied injecting other illicit substances at the time.
Both patients presented to hospital within hours of injecting and the onset of symptoms. Duplex scanning revealed 'severe microvascular spasm secondary to intra-arterial injection of zolpidem'. One patient required emergency treatment with intravenous (IV) heparin to prevent irreversible tissue destruction and loss of digits. The other patient was treated with an anticoagulant infusion and tinzaparin sodium (Innohep) and was given further anticoagulant treatment for a month following discharge.
There have been a limited number of papers suggesting an association between zolpidem and tissue ischaemia. One published paper reported that microcrystalline cellulose, an ingredient in zolpidem, acts as a potent embolic agent resulting in microvascular embolisation and ischaemia. 2 These cases serve to highlight the dangers of intravenous (IV) substance misuse. We regularly inform patients about the risks of injecting illicit substances amongst which include overdose, infective diseases, abscesses, deep venous thrombosis and infective endocarditis. However, we should now highlight the dangers of injecting zolpidem as even a relatively small dose can produce serious consequences. We would like to invite your readers for their comment on similar cases they may have come across within their clinical practice. 
